A Study of Gimatecan (ST1481) in Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This phase Ib/II clinical trial studies the safety and effect of Gimatecan in small cell lung
cancer patients who failed the first-line standard platinum-containing chemotherapy. The
chemotherapy will be given every four weeks.